Atomic AI integrates cutting-edge technologies in machine learning and structural biology, with the goal of unlocking the next generation of RNA-centric medicines, spanning RNA-targeting small molecules and RNA-based therapeutic approaches.
Core technology and main capabilities: The company has developed the ATOM-1 foundation model, which its official website describes as a foundation model for RNA and which can make the world's most accurate predictions of RNA structure and function. This model is the core of its proprietary R&D platform.
How it is used: Its R&D platform integrates ATOM-1 into a "virtuous cycle" and combines it with the company's internally purpose-built wet-lab assays to advance the development of next-generation RNA-centric medicines.
Applicable scenarios: The official website is mainly oriented toward RNA drug discovery, including RNA-targeting small molecules and RNA-based therapies.
Limitations and supplementary information: The materials do not provide information such as specific product pricing, usage thresholds, external access methods, platform calling interfaces, or independently verified results; how its platform and processes are specifically provided externally has not yet been provided.
